Dbv Technologies SA

DBV Technologies reported its second quarter and half-year 2026 financial results, highlighting continued engagement with the FDA for the VIASKIN Peanut Patch BLA submission anticipated in Q3 2026 and sufficient cash reserves into Q3 2027.

DBV Technologies announced a delay in its Biologics License Application submission for the VIASKIN Peanut Patch in children aged 4-7 years, now expected in Q3 2026, following FDA feedback on data formatting.

DBV Technologies has implemented a new performance-based incentive plan for CEO Daniel Tassé, granting 4.06 million share units contingent on FDA approval of Viaskin Peanut by mid-2028.

DBV Technologies S.A. announced the approval of its 2026 Performance Share Unit Plan and a significant PSU grant to CEO Daniel Tass, tied to FDA BLA acceptance for Viaskin Peanut.

DBV Technologies reports a $47.6 million net loss for Q1 2026 while maintaining a cash runway into Q2 2027.

DBV Technologies announced its full-year 2025 financial results, highlighting progress in its VIASKIN Peanut Patch clinical programs and a strengthened financial position.

DBV Technologies reports progress in VIASKIN Peanut development, with a BLA submission anticipated in Q3 2026, alongside increased operating expenses and a net loss for the period.

DBV Technologies reports Q1 2026 financial results, highlighting a $229.2 million cash position and continued progress toward a BLA submission for Viaskin Peanut.

DBV Technologies reports significant regulatory progress for its Viaskin Peanut patch in both toddler and child age groups, backed by recent financing, despite ongoing operating losses and a going concern warning.

DBV Technologies reported increased net losses and a 'going concern' warning, but secured $125.5 million in new financing and achieved significant regulatory alignment with the FDA for its Viaskin Peanut patch in both toddler and child age groups, potentially accelerating market launch.

DBV Technologies provides a Q1 2025 update, highlighting progress with Viaskin Peanut and a new financing strategy to support its development and potential commercial launch.

DBV Technologies' Q3 2024 report details financial results and provides updates on the regulatory pathway for Viaskin Peanut, including a potential accelerated approval in the US.

DBV Technologies reports positive Phase 3 VITESSE results for its Viaskin Peanut patch in children aged 4-7, secures significant financing, and outlines accelerated regulatory pathways for both toddler and child populations in the U.S.

DBV Technologies amends its annual report on Form 10-K to update beneficial ownership information and the description of registered securities.

DBV Technologies provides an overview of its ordinary shares, American Depositary Shares, corporate governance practices, and executive compensation in its amended 10-K filing.

DBV Technologies reports its full year 2024 results and provides updates on its Viaskin Peanut program, including a potential accelerated approval pathway.

DBV Technologies' 10-K filing provides a comprehensive overview of the company's financial status, clinical program advancements, and regulatory strategies, particularly for its Viaskin technology.

Pharis Mohideen, Chief Medical Officer of DBV Technologies S.A., sold 464 shares of common stock on July 29, 2026 for $2.70 per share.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, sold 534 ordinary shares for $4.86 each to cover tax obligations related to restricted stock unit vesting.

Baker Bros. Advisors LP and its affiliated funds exercised significant warrants in DBV Technologies S.A. following the successful VITESSE Phase 3 study.

The Bpifrance group, a 10% owner of DBV Technologies S.A., reported the sale of over 3.3 million ordinary shares across multiple transactions in mid-December 2025.

DBV Technologies' Chief Medical Officer, Pharis Mohideen, reported sales of ordinary shares to cover tax obligations and received new restricted stock units and employee stock options.

DBV Technologies S.A.'s Chief Financial Officer, Virginie Boucinha, was granted 32,000 restricted stock units and 192,000 employee stock options.

DBV Technologies announced its 2026 Annual Combined General Meeting of Shareholders to be held on June 3, 2026, detailing 40 proposals for shareholder vote, including financial statement approvals, director elections, and capital-raising authorities.

DBV Technologies announces its 2025 Annual Combined General Meeting of Shareholders to be held on June 11, 2025, addressing key financial approvals, director renewals, and strategic authorizations.

DBV Technologies is convening its annual shareholder meeting to vote on proposals including financial statement approvals, director renewals, executive compensation, and a potential reverse stock split.

Baker Bros. Advisors and affiliated funds have increased their beneficial ownership in DBV Technologies S.A. to 9.99% following the exercise of warrants.

Bpifrance Participations and its affiliates have filed an exit Schedule 13D/A, reducing their beneficial ownership in DBV Technologies S.A. below 5% after recent share sales.

Bpifrance Participations exercised warrants for 6.5 million DBV Technologies shares and subsequently sold 3.1 million shares in market transactions.

Bpifrance Participations has sold a portion of its DBV Technologies shares and intends to exercise warrants following positive VITESSE trial results, while planning further sales.

Bpifrance and its affiliates report a decreased percentage ownership in DBV Technologies S.A. due to an increase in outstanding shares.

Bpifrance Participations and its affiliated entities have significantly increased their beneficial ownership in DBV Technologies S.A. to 12.2% through a new private placement of Ordinary Shares and warrants.

Adage Capital Management, L.P. has reported beneficial ownership of 7.31% of DBV Technologies S.A. ordinary shares, including shares issuable upon conversion of preferred stock and exercise of warrants.

Artisan Partners Asset Management Inc. and its affiliates have reported beneficial ownership of 3.7% of DBV Technologies S.A. American Depositary Shares.

Vivo Opportunity Fund Holdings and related entities report a combined beneficial ownership of approximately 4.5% in DBV Technologies S.A.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 19,310,005 ordinary shares, representing 6.5% of DBV Technologies S.A.

Vivo Opportunity Fund Holdings and affiliates report a 5.7% beneficial ownership stake in DBV Technologies S.A. ordinary shares.

Invus Public Equities and Avicenna Life Sci Master Fund, along with related entities and Raymond Debbane, reported beneficial ownership of 6.2% of DBV Technologies S.A.'s ordinary shares.